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Purpose: The purpose of this study was to assess the
pharmacokinetic (PK) properties and safety of single
and multiple doses of subcutaneous (SC) pasireotide
and a single-dose intramuscular (IM) long-acting re-
lease (LAR) formulation of pasireotide in Chinese
healthy volunteers (HVs) versus the PK properties in
Western HVs (pooled from previous PK studies).
Methods: In this phase I, single-center, open-label
study, 45 Chinese male HVs were evenly randomized
to 1 to 9 treatment sequences: each volunteer received a
single dose of 300, 600, or 900 μg of pasireotide SC on
day 1, followed by administration of the same dose
BID from day 15 to the morning of day 19, and then a
single IM dose of 20, 40, or 60 mg of pasireotide LAR
on day 33. The PK parameters were assessed with
noncompartmental analysis. Statistical comparison of
PK parameters, including AUC, Cmax, and CL/F from
both formulations, was made for Chinese versus West-
ern male HVs. The safety proﬁle was also assessed.
Metabolic parameters, including blood glucose, insulin,
and glucagon, and measures that reﬂect the effects of
pasireotide LAR on relatively long-term glucose con-
trol, lipid metabolism, and systemic concentrations of
pancreatic enzymes and thyrotropin were evaluated.
Findings: Of the 45 randomized HVs, 42 completed
the study per protocol, 1 withdrew his informed
consent for personal reasons, and 2 prematurely dis-
continued the study because of adverse events (AEs).
Concentration-time and safety proﬁles of both formu-
lations were similar to those reported in Western HVs.
Mean geometric mean ratios (GMRs) of Chinese versus
Western HVs ranged from 0.79 to 1.42. For most
primary PK parameters, 90% CIs for GMRs were1196within a predeﬁned ethnic insensitivity interval (90%
CI, 0.70–1.43). After considering age and weight as
covariates in the statistical model, the GMRs and 90%
CIs for other PK parameters were within the predeﬁned
interval (Cmax in single-dose SC administration) or
signiﬁcantly decreased (Cmin,ss in multiple BID SC doses
and ﬁrst peak Cmax in the single-dose LAR formula-
tion). No serious AEs were reported. Both formulations
were well tolerated; pasireotide SC caused transient
changes in glucose metabolism. Owing to the differ-
ential binding afﬁnity to the somatostatin receptor
subtypes, pasireotide LAR elicited a concentration-
dependent increase of fasting blood glucose, substantial
reduction in triglyceride, and a mild decrease in choles-
terol. The most frequently reported AEs after single-
dose and multiple-dose pasireotide SC were injection
site reaction, nausea, dizziness, and diarrhea; most HVs
developed diarrhea with single-dose pasireotide LAR.
Implications: The pasireotide formulations had
similar PK and safety proﬁles between Chinese and
Western male HVs. Thus, no ethnic sensitivity was
found for pasireotide SC or LAR. (Clin Ther.
2014;36:1196–1210) & 2014 The Authors. Published
by Elsevier HS Journals, Inc.
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Somatostatins are endogenous peptides that exert
broad, mostly inhibitory effects on exocrine and endo-
crine secretions.1 Somatostatin receptor subtypes (ssts)
are expressed in different tissues under normal physio-
logic conditions and in many solid tumors, such as
neuroendocrine tumors.2 Somatostatin analogues (SSAs)
activate these receptors with different potencies, thereby
decreasing cellular activity and subsequently inhibiting
hormone secretion.3
Pasireotide (SOM230) is a cyclohexapeptide SSA.
Like natural somatostatin and other SSAs, pasireotide
exerts its pharmacologic activity through binding to
ssts. Owing to its high-binding afﬁnity to 4 (sst1, sst2,
sst3, and sst5) of the 5 known human ssts, it exhibits a
unique binding proﬁle that is the closest, known thus
far, to natural somatostatin. Compared with the
clinically available SSA octreotide, pasireotide exhibits
a 30- to 40-fold greater binding afﬁnity for sst1 and
sst5, a 5-fold greater binding afﬁnity for sst3, and a
slightly lower (2 times) binding afﬁnity for sst2.4–6
Compared with another SSA, lanreotide, the bind-
ing afﬁnity of pasireotide for sst1, sst3, and sst5 is 19-,
9-, and 106-fold higher, respectively, whereas the
afﬁnity for sst2 is slightly lower (2 times).7 Such a
pharmacologic proﬁle may indicate an improved
efﬁcacy proﬁle for clinical indications currently trea-
ted with octreotide and lanreotide (such as acromegaly
and gastroenteropancreatic neuroendocrine tumors).
Pasireotide may also be beneﬁcial in conditions where
octreotide and lanreotide have not been effective.
Indeed, in 2012, pasireotide was approved by the
European Medicines Agency and the US Food and
Drug Administration for the treatment of adult pati-
ents with Cushing’s disease when surgery has failed or
is not an option.8
Two types of injectable formulations of pasireotide
have been developed: one for subcutaneous (SC) admin-
istration and the other as a long-acting release (LAR)
formulation for intramuscular (IM) injection.9 Previous
studies in the healthy Western population, mainly in
white populations, have provided comprehensive
pharmacokinetic (PK) and safety proﬁle data for
pasireotide SC up to 1500 μg administered as a single
dose or BID doses and for pasireotide LAR 40 and 60
mg administered as a single dose.4,9,10 Moreover,
studies on the clinical efﬁcacy and safety proﬁle of
pasireotide have been performed in patients with
acromegaly,11 Cushing’s disease,12 and neuroendocrineAugust 2014tumors.13 However, there has been little comprehen-
sive PK investigation of an injectable formulation of
pasireotide in Chinese male healthy volunteers (HVs) or
patients. Such a study was expected to assess the PK and
safety proﬁles in Chinese HVs and allow comparison
with Western populations.
The present study evaluated the PK and safety
proﬁles of pasireotide SC and pasireotide LAR in
Chinese HVs and addressed potential ethnic differ-
ences by comparing the PK and safety proﬁles of
Chinese male HVs in this study with those reported in
Western male HVs4,9,10 and unpublished data in
Western HVs from a bioequivalence study with
pasireotide LAR 60 mg (unpublished data on ﬁle,
Novartis Oncology, Clinical Pharmacology, East Han-
over, New Jersey). In addition to the previously
investigated glucose metabolism parameters, including
blood glucose, insulin, and glucagon,4 this study also
tested measures that reﬂect the effects of pasireotide
(pasireotide LAR at 3 different dose levels) on
relatively long-term glucose control, lipid metabolism
and systemic concentrations of pancreatic enzymes,
thyrotropin, and thyroid function measurements.
METHODS
Study Design
This was a Phase I, single-center, open-label,
randomized, 3-period study. All HVs were recruited
into the trial for medical screening. After medical
screening, 45 eligible individuals were randomized on
day 1 to 1 of 9 treatment sequences (Figure 1). The
total study duration was a maximum of 124 days for
each participant, which included a 21-day screening
period, 3 treatment periods (SC single dose - multi-
ple SC BID- IM LAR single dose) separated by two
14-day washout periods and a 70-day follow-up
period after single-dose pasireotide LAR administra-
tion. Participants were allocated (1:1:1) to 1 of the
3 SC dose groups (300, 600, or 900 μg).
This study was sponsored by Novartis Pharmaceut-
ical Corporation. The study was conducted in accord-
ance with the Declaration of Helsinki and complied
with the International Conference of Harmonisation
Harmonised Tripartite Guidelines for Good Clinical
Practice and local laws. The Independent Ethics Com-
mittee of Peking Union Medical College Hospital
(Beijing, China) approved the study protocol. All parti-
cipants provided written informed consent to partici-
pate in the trial.1197
300 µg SC
single dose
300 µg SC BID
20 mg LAR IM single dose
40 mg LAR IM single dose
60 mg LAR IM single dose
20 mg LAR IM single dose
40 mg LAR IM single dose
60 mg LAR IM single dose
20 mg LAR IM single dose
40 mg LAR IM single dose
60 mg LAR IM single dose
600 µg SC
single dose
600 µg SC BID
900 µg SC
single dose
First treatment
period
Day 1
14-Day
washout
period
Second treatment
period
Day 15-19
Third treatment
period
Day 33
14-Day
washout
period
900 µg SC BID
Figure 1. Study design. IM ¼ intramuscular; LAR ¼ long-acting release; SC ¼ subcutaneous.
Clinical TherapeuticsStudy Population
Chinese male HVs age 18 to 45 years who weighed
between 50 and 120 kg, had a body mass index (BMI)
of 18.5 to 30 kg/m2, and had no history of medical
disorders were enrolled. They were assessed as healthy
based on medical history, physical evaluation (including
vital sign measurements), clinical laboratory test results,
abdominal ultrasonography report, and triple 12-lead
ECG. Participants were excluded if they had a QTcF
interval 4450 milliseconds at screening or a history or
clinical evidence of type 1 or type 2 diabetes mellitus or
impaired fasting glucose, psychiatric disorders (includ-
ing depression and anxiety disorders), gallbladder dis-
eases, pancreatic disease, thyroid disease, or other
clinically signiﬁcant disorders. Use of any prescription
or over-the-counter medication (except for paracetamol
[acetaminophen] r2 g/d) within 14 days of the ﬁrst
dosing day or a history within 12 months or evidence
of drug or alcohol abuse also resulted in exclusion.Study Drug and Administration
The pasireotide SC* and LAR formulations were
prepared and supplied to the study center by Novartis.
The pasireotide SC formulation was supplied in 1-mL
vials that contained 300, 600, and 900 μg of pasireotide,
whereas the pasireotide LAR formulation was supplied as*Trademark: Signifors (Novartis, East Hanover, New Jersey).
1198a powder in vials that contained 20 and 40 mg of
pasireotide with a 2-mL vehicle in separate vials (for
reconstitution). Both formulations were administered
immediately after preparation. Participants were required
to stay at the research center on each dosing day and
were conﬁned to the site for 48 hours after the last dose
of each study period. On day 1, a single dose of 300, 600,
or 900 μg of pasireotide SC was injected at approximately
08:00 hours by 2 study nurses after an overnight fast. No
food was permitted until at least 4 hours after dosing. In
the next treatment period, multiple BID SC injections of
the same pasireotide dose were administered at the same
clock time under an overnight fasting condition on the
mornings of days 15, 16, 17, 18, and 19 and 12 hours
later in the evenings of days 15, 16, 17, and 18. Standard
lunch and dinner were provided at 4 hours and 10 hours
after the morning dose, respectively. In the last treatment
period, on day 33, a single IM injection of 20, 40, or 60
mg of pasireotide LAR was administered into study
participants’ left or right gluteal muscle at approximately
08:00 hours in a fasted condition. During this period,
standard meals were provided between 12:00 and 13:00
hours and between 18:00 and 19:00 hours on the days
HVs stayed at the research center.PK Assessments
Blood samples for PK bioanalysis were collected in
the SC single-dose period before dosing and at 0.25,Volume 36 Number 8
X. Chen et al.0.5, 1, 2, 4, 6, 8, 10, and 12 hours on day 1 and 24,
48, 72, 96, 120, and 144 hours after dosing, during
the SC multiple-dose period on days 17 and 18 at
predosing and on day 19 at predosing and a series of
postdose time points identical to those deﬁned for the
SC single-dose period, and after the LAR single-dose
injection on day 33 at predosing and at 0.5, 1, and 2
hours and then 2 hourly up to 12 hours after dosing,
as well as on the ﬁrst and second days, then every 2
days up to 4 weeks, and then weekly up to day 70.
A total of 2.5 mL of blood was collected into a
Monovette EDTA tube for each sample and placed
upright in an ice bath. Within 20 minutes, the samples
were centrifuged (approximately 4ºC, 15 minutes,
approximately 1000g). Immediately after centrifuga-
tion, the plasma was transferred into polypropylene
freezing vials and stored at 201C. Pasireotide plas-
ma concentrations were measured at Atlanbio SA
(Saint-Nazaire, France) using a validated radioimmu-
noassay with a lower limit of quantitation (LLOQ) of
0.15 ng/mL.
For LAR administration, the dosing vial and
injection syringe from each participant were collected
to determine the residual dose using a validated HPLC
method (WuXi AppTech Co, Shanghai, China) with a
LLOQ of 0.15 ng/mL.
The PK parameters were estimated by Phoenix
software, version 6.1 (Pharsight, Mountain View,
California), using noncompartmental analysis (NCA).
The reported NCA PK parameters include AUC1,
Cmax, CL/F, apparent volume of distribution (Vz/F),
and t½ for single-dose pasireotide SC. For SC BID
multiple dose, steady-state PK parameters, including
AUC0–12,ss, Cmax,ss, and CLss/F) were presented. The
accumulation ratio (AR) of SC BID multiple dose was
calculated as AUC0–12,ss on day 19 divided by AUC0–12
on day 1. The NCA PK parameters for LAR single-
dose administration include Cmax (of the ﬁrst peak
[Cmax,p1] and second peak [Cmax,p2]), AUC1, CL/F,
Vz/F, and t½. In addition, the relative bioavailability
of LAR using the SC single dose in the same HVs as
reference was determined. For the PK data from LAR
single-dose administration, the exact dose (corrected
for residual dose) was used in the NCA.
Safety Assessments
Adverse events (AEs) were identiﬁed throughout
the study. During each treatment period, vital signs,
12-lead ECG, and clinical laboratory evaluationsAugust 2014(clinical chemical analysis, hematologic testing, and
urinalysis) were recorded.
Blood samples to assess fasting insulin, fasting
glucagon, fasting blood glucose, and α-amylase assays
were collected before dosing and at 0.5, 1, 2, 4, 6, and
8 hours after dosing on day 1. For the multiple-dose
SC period, these measurements were taken before
dosing in the morning on day 19 (the last dosing
day) and at the same postdosing time points as that
for the SC single-dose period, after the last morning
dose on day 19. For single-dose IM LAR formulation
administration, these measurements were taken before
dosing and at the same time points after dosing as for
the single-dose SC period. As follow-up, these evalua-
tions were also performed 2 days after administration
of the LAR dose, followed by every alternate day for 4
weeks and then weekly up to 70 days after dosing.
Lipase assay was performed at screening, at the
predosing time points on the ﬁrst and fourth days of
the multiple-dose SC period, and before dosing and on
6, 20, 28, and 70 days after the single-dose pasireotide
LAR dose.
Both 1,5-anhydroglucitol (1,5-AG) and glycosy-
lated hemoglobin (HbA1c) were measured to evaluate
blood glucose homeostasis during the study. Blood
samples for 1,5-AG assays were taken before dosing in
each period and on days 6, 14, and 22 after the single-
dose pasireotide LAR dose. HbA1c was measured at
screening, before dosing of the multiple-dose SC
period and the LAR period, and on day 70 of the
LAR dose. In addition, thyrotropin, thyroid function
(free and total thyroxine), cholesterol, and triglyceride
were assessed at screening, before the ﬁrst dose in the
multiple-dose SC period and before dosing, and on
days 6, 20, 28, and 70 after a single dose of the LAR
formulation.
Laboratory samples of glucose, insulin, glucagon,
1,5-AG, and HbA1c were assessed by Quintiles Cen-
tral Laboratory (Beijing, China), and the assays of
hematologic tests and blood chemical tests other than
glucose, α-amylase, thyrotropin, and thyroid function
were performed by the central laboratory of Peking
Union Medical College Hospital.
Statistical Analysis
The PK set (by treatment) consisted of all HVs who
received at least a single dose of pasireotide and
provided evaluable PK proﬁles for at least one treat-
ment period. The safety set included all HVs who1199
Clinical Therapeuticsreceived at least one dose of pasireotide (even those
who took only part of the scheduled dose for a
treatment day were considered).
Descriptive statistics of PK parameters from NCA
in Chinese HVs were summarized by single-dose
pasireotide SC and multiple-dose BID treatments and
by single-dose LAR treatment. The primary PK pa-
rameters, including Cmax, AUC1, and CL/F for single-
dose pasireotide SC; AR, Cmax,ss, AUC0–12,ss, and
CLss/F for multiple-dose pasireotide SC BID; and
Cmax,p1, Cmax,p2, AUC1, and CL/F for single-dose
pasireotide LAR from both Chinese HVs and those
pooled Western HVs were compared using a statistical
model:
Yijk¼μþ αiþβ  xjþεijk
in which, Yijk denotes log-transformed (natural base)
primary PK parameters mentioned above for indi-
vidual k from region i (i ¼ 1,2; Chinese or Western)
treated with j dose level (single-dose pasireotide SC,
multiple-dose SC BID, or single-dose LAR), xj
denotes log of dose j, and εijk is the error assumed
to be independent and identically normal distrib-
uted with mean 0 and variance σ2. The parameter μ
refers to overall mean, αi is the effect of region i,
and β is the slope parameter. In addition, weight
and age were also explored as covariates. To assess
the dose-exposure relationship between Chinese
and Western study participants, the point estimates
and 90% CIs for mean difference between these 2
regions for these primary PK parameters (in log
scale) of the pasireotide SC single dose, SC multiple
BID doses, and LAR single dose were calculated
between Chinese and Western HVs based on the
above model. This point estimate and its corre-
sponding 90% CI were antilogged to obtain the
point estimate and the 90% CI for geometric mean
ratio (GMR) in the original scale. If the 90% CI for
the GMR of the primary PK parameters in the
original scale between these 2 regions (Chinese
and Western) were contained in the range of 0.70
to 1.43, it would be claimed that Chinese and
Western HVs are similar in a dose-exposure rela-
tionship (ie, there is no ethnic difference on PK
parameters between Chinese and Western HVs for
pasireotide). The ethnic insensitivity interval (90%
CI, 0.70–1.43) was determined based on high
intersubject PK variability of pasireotide SC ob-
served in HVs and patients.4,9,10,131200The dose proportionality of pasireotide was eval-
uated for single SC, multiple SC, and single LAR doses
with a power model,14 in which simple linear
regression was applied to log-transformed PK param-
eters and log-transformed dose as follows: ln(PK
parameter) ¼ ln(a) þ b*ln(dose) þ error. The point
estimate and associated 90% CI for the slope param-
eter b were provided and compared with the target
region (90% CI, 0.80–1.25) for a maximum dose ratio
of 3 (300–900 mg and 20–60 mg).
For safety proﬁle assessments, baseline was period
speciﬁc with day 1 baseline deﬁned for the SC single
dose, day 15 baseline for the multiple doses, and day
33 baseline for the LAR single dose. Proﬁles of insulin,
glucagon, and glucose were graphically presented as
the percentage of changes from baseline against time.
The log-transformed overall percentage responses
were also compared using a mixed-effect linear model,
with ﬁxed factors of treatment and time point and
random factors of study participant and study partic-
ipant by time. The estimates of ﬁxed effects were
calculated within the statistical model for different
study periods. Contrasts between any 2 dose groups
were reported along with their 95% CIs for the LAR
period. All statistical analyses were performed with
SAS statistical software, version 9.2 (SAS Institute,
Cary, North Carolina).RESULTS
Participant Demographic Characteristics
and Disposition
A total of 45 male HVs were randomized to 1 of
the 9 treatment sequences; 42 completed the study per
protocol. Two HVs prematurely discontinued study
treatment because of AEs, 1 during the single-dose
pasireotide SC period and the other during the
multiple-dose SC BID period. One HV withdrew his
informed consent shortly after receiving single-dose
pasireotide SC 900 mg for personal reasons. These 3
dropout cases were still included in safety assessments.
For PK analysis, HVs whose full PK proﬁles were
available were included.
All HVs randomized in this study were Chinese men,
with a mean (SD) age of 28.8 (6.55) years, weight of
62.8 (7.76) kg, and BMI of 22.5 (2.14) kg/m2. Demo-
graphic parameters were similar among the 3 dose
groups of each pasireotide formulation and across the
9 treatment sequences (Table I).Volume 36 Number 8
Table I. Demographic and baseline characteristics of the study participants.*
Variable
Single-Dose Pasoreotid SC Single-Dose Pasireotid LAR
300 mg†
(n ¼ 15)
600 mg†
(n ¼ 15)
900 mg†
(n ¼ 15)
20 mg
(n ¼ 15)
40 mg
(n ¼ 14)
60 mg
(n ¼ 13)
Age, y 30.2 (8.20) 28.6 (6.66) 27.7 (4.48) 27.3 (5.92) 28.7 (6.35) 29.6 (7.34)
Weight, kg 61.7 (6.42) 64.1 (7.33) 62.5 (9.53) 61.8 (5.68) 64.5 (10.23) 63.2 (7.46)
Height, cm 165.6 (6.82) 168.2 (6.21) 166.5 (7.59) 167.2 (6.88) 169.1 (6.06) 164.9 (7.41)
BMI, kg/m2† 22.5 (1.33) 22.7 (2.31) 22.5 (2.69) 22.2 (2.29) 22.4 (2.31) 23.2 (1.98)
BSA, m2 1.695 (0.116) 1.739 (0.117) 1.708 (0.151) 1.702 (0.095) 1.746 (0.162) 1.712 (0.127)
BMI ¼ body mass index; BSA ¼ body surface area; LAR ¼ long-acting release; SC ¼ subcutaneous; y = year.
*Data are presented as mean (SD).
†Demographic and baseline characteristics for the pasireotide SC BID doses in Chinese male healthy volunteers are not
presented here; they were similar to those for the corresponding pasireotide SC single-dose groups.
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Single-Dose Pasireotide SC PK Profile
Pasireotide arithmetic mean (SD) concentration-
time proﬁles after single doses of pasireotide SC of
300, 600, or 900 mg are given on semilog scales in
Figure 2A. Pasireotide was rapidly absorbed after SC
injection, with the maximum concentration being
reached in a median Tmax of 0.5 hour after dosing
at all dose levels. Plasma pasireotide concentrations
subsequently declined triexponentially during the 144-
hour observation period for all test dose levels. The
summary of descriptive statistics of PK parameters for
single-dose pasireotide SC is presented in Table II. The
t½ ranged from 9.6 to 12.6 hours. The CL/F was
relatively constant (range, 7.3–8.4 L/h) across the 3
dose levels. The AUC1 and Cmax increased with dose
level. In the dose-exposure proportionality analysis,
the estimated slope for AUC1 was 0.90, with a 90%
CI of 0.73 to 1.07. For the Cmax, the estimated slope
was 1.13, with a 90% CI of 1.00 to 1.25.Multiple-Dose BID Pasireotide SC PK Profile
For the SC multiple BID dosing, pasireotide plasma
concentration-time proﬁles after the last morning dose
in the multiple-dose SC period were similar to the SC
single-dose proﬁles (Figure 2B). The summary of des-
criptive statistics of PK parameters from pasireotide SC
multiple BID dosing is given in Table II. The AR rang-
ed from 1.39 to 1.53 and was relatively constant for
the 3 dose levels. The AUC0–12,ss and Cmax,ss increasedAugust 2014in a dose-dependent manner. The estimated slope in the
dose proportionality analyses for AUC0–12,ss was 1.03,
and the 90% CI for the slope was 0.80 to 1.20. The
estimated slope for Cmax was 1.15, and the 90% CI for
the slope estimate was 1.03 to 1.27.Single-Dose Pasireotide LAR PK Profile
After a single IM injection of pasireotide LAR at 20,
40, or 60 mg, an initial burst release of pasireotide was
seen within 24 hours followed by a decrease from days
1 to 4. Thereafter, the plasma concentration increased
gradually from day 6, reached a plateau at approx-
imately day 20 (median second Tmax peaks in the 20-,
40-, and 60-mg LAR formulations were 16, 18, and 20
days, respectively), and ended with a slow elimination
phase (Figure 2C). The ﬁrst peak plasma level of
pasireotide was generally lower than the second peak
for all tested doses (Figure 2C and Table II). The
relative bioavailability (using the single-dose pasireotide
SC PK proﬁle as the reference) was slightly 41. The
CL/F was constant for the LAR dose range of 20 to 60
mg. In the dose proportionality analysis, the estimated
slopes for AUC1 and Cmax,p2 (0.99 and 1.04, respec-
tively) suggested a dose-proportional relationship. The
estimated slope for Cmax,p1 was low at 0.53, with a
90% CI of 0.35 to 0.71. This parameter mainly
represents the initial release and peak concentration
on day 1 immediately after IM injection. Because
Cmax,p1 has a lower or comparable level compared
with Cmax,p2, it would have much less signiﬁcant effect1201
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Figure 2. Arithmetic mean (SD) plasma concentration-time profiles of pasireotide. (A) Single subcutaneous
(SC) doses (300, 600, and 900 μg). (B) Multiple BID SC doses (300, 600, and 900 μg) after the last
morning (ninth) SC dose. (C) Single long-acting release (LAR) doses (20, 40, and 60 mg).
Clinical Therapeuticsthan Cmax,p2 on steady-state plasma exposure in multi-
ple dosing regimen, especially at therapeutic doses of
40 mg or above.
The Vz/F was large (43500 L) for 20, 40, and 60
mg. However, this Vz/F value was most likely over-
estimated owing to the ﬂip-ﬂop PK characteristics of
pasireotide LAR. The actual volume of distribution
should be better estimated by using the SC formula-
tion data, with Vz/F ranging from 90.7 to 154.6 L.
The t½ ranges from 375.7 to 443.2 hours, much1202longer than that in the SC single dose; again, this is
due to the ﬂip-ﬂop phenomenon associated with slow
release of pasireotide from the LAR formulation.
Statistical Comparison of Primary PK Parameters
Between Chinese and Western Male HVs
The results of statistical comparison of primary PK
parameters between Chinese and Western male HVs
are summarized in Table III. After single pasireotide
SC doses, the 90% CI for the GMRs of the primaryVolume 36 Number 8
Table II. Summary of primary pharmacokinetic parameters for plasma pasireotide by treatment in Chinese
male healthy volunteers (pharmacokinetic set).*
Drug Low Dose Medium Dose High Dose
Pasireotide SC single dose 300 mg (n ¼ 15) 600 mg (n ¼ 15) 900 mg (n ¼ 15)
AUC1, ng  h/mL 46.5 (17.67) 78.3 (23.61) 123.2 (34.36)
Cmax, ng/mL 9.8 (2.07) 20.4 (7.08) 33.9 (5.77)
CL/F, L/h 7.3 (2.55) 8.4 (2.58) 7.8 (2.09)
Vz/F, L 90.7 (30.84) 142.7 (85.73) 154.6 (103.45)
t½, h 9.6 (4.88) 12.6 (8.56) 11.6 (4.3)
Tmax, median (range), h 0.5 (0.25–1.00) 0.5 (0.25–1.00) 0.5 (0.25–1.00)
Pasireotide SC BID 300 mg (n ¼ 14) 600 mg (n ¼ 14) 900 mg (n ¼ 14)
Cmax,ss, ng/mL 11.6 (2.72) 25.6 (4.46) 40.4 (5.76)
AUC0–12,ss, ng  h/mL 45 (13.52) 84.4 (15.06) 136.2 (18.97)
AR† 1.4 (0.22) 1.5 (0.27) 1.5 (0.42)
Pasireotide LAR single dose 20 mg (n ¼ 15) 40 mg (n ¼ 14) 60 mg (n ¼ 13)
AUC1, ng  h/mL‡ 3260 (720) 6274 (1777) 9915 (2596)
CL/F, L/h 6.4 (1.27) 6.8 (1.76) 6.4 (1.62)
Vz/F, L 3895 (1542) 3674 (1602) 3583 (1181)
t½, h 443.2 (202.28) 375.7 (140.63) 399 (137.4)
Cmax,p1, ng/mL
‡ 6.7 (2.54) 9.4 (3.25) 11.9 (2.94)
Cmax,p2, ng/mL
‡ 6.1 (1.51) 12 (4.82) 19.6 (5.27)
BALAR/SC 1.18 (0.23) 1.20 (0.22) 1.32 (0.35)
AR ¼ accumulation ratio; BA ¼ bioavailability; Cmax,p1 ¼ Cmax of the ﬁrst peak; Cmax,p2 ¼ Cmax of the second peak;
LAR ¼ long-acting release; SC ¼ subcutaneous; Vz/F ¼ apparent volume of distribution.
*Data are presented as mean (SD) unless otherwise indicated.
†The AR after multiple SC BID dosing was assessed based on AUC0–12,ss divided by AUC0–12 on day 1 of SC single dose.
‡The pharmacokinetic parameters AUC1, Cmax,p1, and Cmax,p2 for the pasireotide LAR treatments are corrected based on the
exact doses of LAR ([parameter/exact dose]  planned dose).
X. Chen et al.PK parameters (AUC1 and CL/F) were completely
within the predeﬁned target interval of 0.70 to 1.43,
whereas the 90% CI for the GMRs of the primary PK
parameter Cmax extended above the upper bound of
the target interval.
After pasireotide SC BID doses at steady state, the
PK parameters (AUC0–12,ss, Cmax,ss, and CLss/F) in
Chinese HVs were similar to those of Western HVs.
All 90% CIs of the GMRs for these 3 PK parameters
were within the predeﬁned interval of 0.70 to 1.43.
For AR too, the 90% CI of the GMR of Chinese
compared with Western HVs was within the interval
of 0.70 to 1.43. The combined statistical analysis of
primary PK parameters from single and multiple SC
dosing suggests that there was no clinically relevantAugust 2014PK exposure difference between Chinese and Western
male HVs after SC administration of pasireotide.
Similarly, after pasireotide LAR doses, the PK pa-
rameters (AUC1, Cmax,p2, and CL/F) in Chinese male
HVs were similar to those of Western male HVs. All
90% CIs of the GMRs for these 3 PK parameters were
within the predeﬁned target interval. Although Cmax,p1
was 75% higher in Chinese male HVs and the 90% CI
of its ratio (1.39–2.21) was out of the predeﬁned target
interval, the effect of Cmax,p1 related to the initial burst
release may be less signiﬁcant (because of the addition of
high-level predose concentrations that are more relevant
to Cmax,p2 on day 28 in a monthly dosing regimen) at
steady state after multiple dosing, especially at doses of
Z40 mg. Thus, there was no clinically relevant PK1203
Table III. Statistical analysis of primary pharmaco-
kinetic parameters for plasma pasireotide
(pharmacokinetic set).
Treatment received GMR (90% CI)*
Pasireotide SC single dose
AUC1, ng  h/mL 1.18 (1.06–1.30)
Cmax, ng/mL 1.42 (1.28–1.56)
CL/F, L/h 0.85 (0.77–0.94)
Pasireotide SC BID
Cmax,ss, ng/mL 0.79 (0.70–0.89)
AUC0–12,ss, ng  h/mL 1.20 (1.06–1.35)
AR 0.90 (0.80–1.00)
Pasireotide LAR single dose
AUC1, ng  h/mL 1.03 (0.92–1.16)
CL/F, L/h 0.97 (0.86–1.08)
Cmax,p1, ng/mL 1.75 (1.39–2.21)
Cmax,p2, ng/mL 1.08 (0.93–1.25)
AR ¼ accumulation ratio; Cmax,p1 ¼ Cmax of the ﬁrst
peak; Cmax,p2 ¼ Cmax of the second peak; GMR ¼
geometric mean ratio; LAR ¼ long-acting release; SC ¼
subcutaneous.
*Point estimates and 90% CIs for the GMR are calcu-
lated for Chinese healthy volunteers and Western
healthy volunteers from an analysis of variance on
the log-transformed pharmacokinetic parameter with
region and dose as the main effects.
Clinical Therapeuticsexposure difference after single-dose pasireotide LAR
between Chinese and Western male HVs.
Safety Profile Results
Adverse Events
No serious AEs were reported during the study. AEs
are summarized as preferred terms by treatment in
Table IV. One participant discontinued study treatment
from the multiple-dose SC period onward because of
the development of frequent supraventricular extrasys-
toles on day 1 after receiving a single dose of 300 μg of
pasireotide SC. Another participant withdrew his con-
sent because of moderate diarrhea and abdominal pain
during treatment with 600 μg SC BID.
Overall, 44 of 45 HVs (97.8%) reported at least 1
AE during the study. The 1 HV who did not report any
AEs withdrew his consent for personal reasons after a
single SC dose of 900 μg. The most frequently reported
AEs were injection site reaction, nausea, dizziness, and1204diarrhea after single-dose pasireotide SC and multiple-
dose pasireotide SC, with relatively higher incidence
observed after the latter. In addition, abdominal pain
and discomfort were reported by approximately one-
third of the HVs in each dose group during the
multiple-dose SC period. The incidences of these AEs
did not reveal a dose-dependent trend of increase.
After a single dose of pasireotide LAR, most HVs
developed diarrhea. Elevated levels of blood glucose
and lipase were reported more frequently with 40 and
60 mg of pasireotide LAR. Injection site reaction,
dizziness, and nausea were less frequent during the
LAR period compared with the single- and multiple-
dose SC periods.
In the follow-up visit scheduled on day 70 of the
LAR period, gallbladder polyp was reported for 3
HVs based on their results of abdominal ultrasonog-
raphy examination. All these gallbladder polyps had a
diameter smaller than 0.5 cm, were judged as mild in
severity, and required no medical intervention.
Glucose, Insulin, and Glucagon
The 8-hour postdose proﬁles of glucose, insulin, and
glucagon are presented in Figure 3. The change-from-
baseline proﬁles of fasting glucose were similar to those of
plasma pasireotide concentration during the 70-day LAR
treatment period, when a rapid 20% to 30% increase was
seen shortly after LAR injection, followed by a relatively
shunt peak that appeared between 10 and 20 days after
dosing (Figure 4A). The overall increases in blood glucose
were larger with pasireotide LAR 60 mg (mean overall
change, 23.2%; 95% CI, 18.9%–27.6%) than with LAR
20 mg (mean overall change, 16.1%; 95% CI, 12.5%–
19.9%; 60 vs 20 mg; P ¼ 0.016) and marginally larger
than with LAR 40 mg (mean overall change, 18.0%;
95% CI, 14.0%–22.2%; 60 vs 40 mg; P ¼ 0.080).
In all treatment periods, the level of insulin stayed
low for the ﬁrst 4 hours after dosing and could not be
fully evaluated because of a relatively high LLOQ (14
mU/L) of insulin assay. Insulin quickly increased after
meal and returned to baseline level between 4 and 8
hours after dosing. The mean concentration of gluca-
gon initially subsided and then gradually increased to
its baseline level during the 8 hours after SC pasireo-
tide. A much slower decrease in glucagon was seen
after IM pasireotide LAR, where a trough concen-
tration occurred approximately 8 hours after dosing.
As such, a slight increase in mean blood glucose was
observed during the fasting section and was followedVolume 36 Number 8
Table IV. Number (percentage) of adverse events with an incidence of at least 20% in at least 1 treatment by
preferred term and treatment (safety set).
Adverse event Low Dose Medium Dose High Dose
Pasireotide SC single dose 300 mg (n ¼ 15) 600 mg (n ¼ 15) 900 mg (n ¼ 15)
Injection site reaction 12 (80) 10 (67) 9 (60)
Diarrhea 2 (13) 2 (13) 3 (20)
Nausea 5 (33) 7 (47) 6 (40)
Dizziness 2 (13) 2 (13) 6 (40)
Pasireotide SC BID 300 mg (n ¼ 14) 600 mg (n ¼ 15) 900 mg (n ¼ 14)
Injection site reaction 14 (100) 14 (93) 12 (86)
Abdominal discomfort 4 (29) 5 (33) 5 (36)
Abdominal pain 5 (36) 2 (13) 4 (29)
Diarrhea 8 (57) 8 (53) 9 (64)
Nausea 6 (43) 7 (47) 8 (57)
Mouth ulceration 2 (14) 3 (20) 0 (0)
Dizziness 6 (43) 4 (27) 5 (36)
Nasopharyngitis 3 (21) 1 (7) 1 (7)
Back pain 3 (21) 1 (7) 0 (0)
Pasireotide LAR single dose 20 mg (n ¼ 15) 40 mg (n ¼ 14) 60 mg (n ¼ 13)
Abdominal discomfort 2 (13) 3 (21) 0 (0)
Abdominal pain 2 (13) 3 (21) 0 (0)
Diarrhea 11 (73) 12 (86) 9 (69)
Blood glucose increased 4 (27) 4 (29) 6 (46)
Blood thyrotropin increased 1 (7) 3 (21) 2 (15)
Lipase increased 3 (20) 5 (36) 6 (46)
Nasopharyngitis 6 (40) 4 (29) 1 (8)
Pharyngitis 3 (20) 1 (7) 2 (15)
Rhinitis 1 (7) 1 (7) 3 (23)
Injection site reaction 3 (20) 3 (21) 1 (8)
Dizziness 2 (13) 3 (21) 0 (0)
Headache 2 (13) 3 (21) 1 (8)
Gallbladder polyp 0 (0) 0 (0) 3 (23)
LAR ¼ long-acting release; SC ¼ subcutaneous.
X. Chen et al.by a much larger surge of glucose in the postprandial
section of each dosing period.
1,5-AG and HbA1c
The level of 1,5-AG decreased during the 22 days
after dosing in a dose-related manner (P ¼ 0.047).
The largest estimated overall geometric mean changes
(negative values represent reduction from baseline)
were found in HVs treated with pasireotide 60 mg (20
vs 60 mg: 4.4% [95% CI, 7.4% to 1.4%] vsAugust 201410.0% [95% CI, 13.0% to 6.9%], P ¼ 0.014;
40 vs 60 mg: 7.1% [95% CI, 10.1% to 4.1%] vs
10.0% [95% CI, 13.0% to 6.9%], P ¼ 0.192)
(Figure 4B). The levels of HbA1c were generally
comparable between baseline and day 70 among the
3 LAR dose groups.
Triglyceride and Cholesterol
Serum cholesterol levels were slightly and non-
signiﬁcantly decreased at approximately 20 to 30 days1205
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Figure 3. Mean (SD) plasma concentration-time profiles of glucose, insulin, and glucagon up to 8 hours after dosing. (A) Single subcutaneous (SC)
doses (300, 600, and 900 μg). (B) Multiple BID SC doses (300, 600, and 900 μg). (C) Single long-acting release (LAR) doses (20, 40, and
60 mg). Because a standard lunch was provided shortly after 4 hours after dosing, the 8-hour postdose profiles consist of a fasting section
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Figure 4. Geometric mean overall percentage change from baseline profiles of fasting glucose (A), 1,5-
anhydroglucitol (1,5-AG) (B), cholesterol (C), and triglyceride (D) during the single-dose long-
acting release (LAR) period with 20, 40, or 60 mg of pasireotide LAR.
X. Chen et al.after dosing during the LAR period (Figure 4C). The
mean triglyceride levels were below baseline levels
from 6 to 28 days after the LAR doses and restored to
their predose levels on day 70 (Figure 4D). The
reduction in triglyceride levels was similar among
the 3 doses of pasireotide LAR (Figure 4D).
Amylase and Lipase
None of the pasireotide doses administered in the
single and multiple SC periods caused a statistically
signiﬁcant change from baseline in amylase or lipase
levels during the ﬁrst 8 hours after dosing. Likewise,
the postdose values of amylase or lipase did not
signiﬁcantly differ from the baseline levels in any of
the dose groups in the LAR period.
Thyrotropin and Thyroid Function
The levels of thyrotropin and thyroid function had
small ﬂuctuations during the LAR period, which did
not suggest any dose-related or time-dependent
changes.August 2014ECG and Vital Signs (Heart Rate and Blood Pressure)
Only minor deviations from normal were found in
ECG tracings. No QTcF 4480 milliseconds was rep-
orted. An increase of 430 milliseconds in QTcF was
reported for 1 HV after the 900 μg SC BID dose and
no increase of 460 milliseconds was recorded. No
trends over time or between dose levels and pasireo-
tide formulations were observed in the mean and
median measurements of heart rate or blood pressure.DISCUSSION
The concentration-time proﬁles of pasireotide SC
(300, 600, and 900 mg) single and multiple BID doses
in Chinese HVs exhibited triexponential disposition
characteristics as observed previously in Western
HVs.4,9,10 The contribution of the partial AUC in
the terminal γ phase (in triexponential disposition
proﬁles) to AUC1 was minimal in pasireotide SC
PK proﬁles. Pasireotide was rapidly absorbed, with
Cmax observed at approximately 0.5 hour after dosing1207
Clinical Therapeutics(Tmax) in both Chinese and Western HVs. The absorp-
tion and disposition phases of pasireotide were similar
between Chinese and Western HVs. After SC multiple
BID dosing, the PK proﬁles were similar to those after
SC single dosing with low accumulation (AR of
approximately 1.5). After a single pasireotide LAR
dose, the plasma concentration versus time proﬁles in
Chinese HVs were also similar to those of Western
HVs, revealing an initial burst release proﬁle, a slow
release for 2 to 5 days, a plateau concentration at
approximately day 20, and a slow elimination there-
after. In contrast to PK proﬁles of the SC formulation,
the absorption phase is very slow from the LAR
formulation as evidenced by the ﬂip-ﬂop kinetics of
the LAR PK proﬁles in both Chinese and Western HVs.
After the SC single dose, although the geometric
mean AUC1 and Cmax levels in Chinese HVs were
slightly higher than Western HVs, the magnitudes of
differences were moderate (18% and 42%, respec-
tively). Because the overall mean weights of Chinese
HVs were approximately 10 to 20 kg lower than those
of the Western study HVs,4,10 statistical adjustment
with the weight was warranted to evaluate the ethnic
differences of PK parameters between Chinese and
Western HVs. Indeed, weight and age, were both
identiﬁed as statistically signiﬁcant factors correlated
with the PK properties of pasireotide. This result is
consistent with the ﬁndings in population nonlinear
mixed-effects modeling of pasireotide SC PK assess-
ment in Westerner HVs and linear mixed-effects
modeling of pasireotide LAR PK assessment in patients
with acromegaly disease (data not given). After adjust-
ment for the covariates of age and weight, the magni-
tudes of differences (Chinese vs Western HVs) were
only 14% and 13% for AUC1 and Cmax parameters
(data not given), respectively. The 90% CI for the
GMRs of the PK exposure parameters (AUC1, Cmax,
and CL/F) were completely within the predeﬁned target
interval (90% CI, 0.701.43). In addition, after multi-
ple SC BID doses of pasireotide until steady state,
GMRs of AR, AUC012,ss, Cmax,ss, and CLss/F were all
within the predeﬁned target interval of 0.70 to 1.43.
The combined results from both SC single and multiple
BID doses suggest the PK parameters of Chinese and
Western male HVs are comparable.
The PK parameters in Chinese male HVs were also
comparable to those of Western male HVs after single
LAR dosing. There are only 3% difference in AUC1,
8% for Cmax,p2, and 3% for CL/F. The relatively large1208difference observed for Cmax,p1 (GMR, 1.75; 90% CI,
1.392.21) may not be that clinically signiﬁcant
because Cmax,p1 mainly represents an initial drug
release (ie, from drug residue on the surface of
microparticle) after IM injection on day 1, and its
level is generally lower than or comparable to Cmax,p2.
Because the partial AUC (from 0 to 24 hours after
LAR due to initial burst release)–associated Cmax,p1 is
much smaller than that related to Cmax,p2 because of
sustained high concentrations around Cmax,p2 from
the slow release proﬁle, the contribution of Cmax,p1 to
the overall plasma exposure of pasireotide is consid-
ered not clinically relevant. In addition, the GMR of
Cmax,p1 was decreased from 1.75 to 1.31 on adjust-
ment with covariates of weight and age, but the upper
bound of its 90% CI of 1.01 to 1.72 is still outside the
target boundary of 0.70 to 1.43.
An approximate dose-proportional relationship was
observed for AUC and Cmax after single and multiple SC
BID doses of 300 to 900 mg, as well as after single IM
LAR doses of 20, 40, and 60 mg. These results add to
our knowledge regarding the PK properties of SC and
LAR formulations of pasireotide in Chinese male HVs
and are consistent with the linearity of pasireotide PK
properties concluded from studies with pasireotide SC
and LAR in Western male HVs.4,9 The values of CL/F
were similar between the 2 formulations of pasireotide,
suggesting the systemic elimination of pasireotide is
independent of the formulation administered.
This study also investigated the effects of pasireo-
tide, particularly pasireotide LAR, on glucose metabo-
lism, lipid proﬁle, and other endocrinal and pancreatic
agents. The blood glucose level changed, almost imme-
diately, with plasma pasireotide. Hence, a pulse like
increase in fasting glucose was seen during the LAR
dosing day, followed by a much slower surge in
approximately 2 to 5 days. Interestingly, this proﬁle
was similar to the double-peak concentration-time
proﬁle of plasma pasireotide LAR, which, in conjunc-
tion with the dose-related overall glucose increments,
indicated a concentration-dependent effect of pasireo-
tide on fasting blood glucose. The effect of pasireotide
LAR on glucose metabolism is complex. On one hand,
pasireotide suppressed insulin secretion through mod-
iﬁcation of sst1 and sst5 on the islet β-cells, and on the
other hand, it reduced the production of glucagon by
acting on sst2 that expresses on the islet α-cells.15 The
balance of these 2 effects determines whether
pasireotide LAR impairs glucose metabolism or not.Volume 36 Number 8
X. Chen et al.Because the suppressed levels of insulin and glucagon
were frequently below the LLOQ of these bioassays,
the expected changes in either insulin or glucagon were
not observed during the LAR period. Increases in the
fasting glucose levels indicate that pasireotide LAR has
a stronger afﬁnity for sst5 than for sst2. Although the
level of HbA1c was stable during the LAR period, the
dose-related decreases in 1,5-AG provided further
evidence about glucose excursions and were attributed
to the effect of pasireotide.
Pasireotide LAR considerably decreased triglyceride
levels. Similar ﬁndings were reported in previous studies
with other SSAs, such as octreotide LAR16 and the
slow-released formulation of lanreotide,17 in patients
with acromegaly. Other studies found that animals with
metabolic syndrome had relatively lower somatostatin
levels and that administration of exogenous SSAs
improved hypertriglyceridemia.18 Therefore, the effect
of pasireotide on triglyceride may be related to the
physiologic functions of natural somatostatin.
Overall, single and multiple doses of pasireotide SC
and the single IM dose of pasireotide LAR were safe
and well tolerated in Chinese HVs. The observed AE
proﬁle was as expected based on previous studies of
pasireotide LAR,9 pasireotide SC,4 or other SSAs.19
This study was not designed as a blind and
placebo-controlled trial. Interpretations of treatment-
related AEs should keep these limitations in mind.
Moreover, the selection of male HVs as study partic-
ipants may weaken the clinical relevance of those
endocrinal outcomes.
CONCLUSION
The 2 formulations (SC and LAR) of pasireotide had
similar PK and safety proﬁles between Chinese and
Western male HVs at the same dose levels. No clinically
relevant ethnic PK exposure differences were found
between Chinese and Western male HVs after SC
pasireotide or pasireotide LAR doses when age and
weight were included in the analysis model as covariates.
As in the Western population, pasireotide SC induced
transient changes in glucose metabolism; pasireotide
LAR increased fasting glucose levels and reduced trigly-
ceride levels in a dose-dependent manner.
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